Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910568 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT04910568: Active Phase 1 study of Multiple Myeloma, sponsored by Genentech.
NCT04910568 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 126 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910568, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Tocilizumab
- DRUG Cevostamab
Study Locations (20)
Other
- Fakultni Nemocnice Ostrava - Ostrava
- Rigshospitalet - København Ø
- Hôpital Saint-Louis - Paris
- CHU de Poitiers - La Miletrie - Poitiers
- Rambam Medical Center - Haifa
- Yamagata University Hospital - Yamagata
- Pratia Onkologia Katowice - Katowice
- Uniwersytecki Szpital Kliniczny w Poznaniu - Późna
California
- City of Hope - Duarte
- City of Hope - Lennar Foundation Cancer Center - Irvine
Victoria
- Peter MacCallum Cancer Centre - Melbourne
- The Alfred Hospital - Melbourne
Ontario
- Hamilton Health Sciences - Hamilton
- University Health Network - Toronto
Lombardy
- Asst Papa Giovanni Xxiii - Bergamo
- A.O. Spedali Civili Di Brescia-P.O. Spedali Civili - Brescia
Colorado
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center - Denver
Michigan
- Karmanos Cancer Institute. - Detroit
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2029-12-10 |
| Phase | Phase 1 |
What the registry record for NCT04910568 still lists
NCT04910568 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT04910568 names 20 study sites across 9 states, led by Other, California, Victoria.
Frequently Asked Questions
What is clinical trial NCT04910568 about?
NCT04910568 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma". This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to par...
What is the current status of trial NCT04910568?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-07-26. Estimated completion is 2029-12-10.
What conditions does trial NCT04910568 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04910568?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Tocilizumab (DRUG), Cevostamab (DRUG).
Who is sponsoring clinical trial NCT04910568?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04910568 being conducted?
This trial has 20 study locations across California, Colorado, Michigan, Missouri, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04910568's enrollment target sits among peer trials
126 147th of 438 higher than 292 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI